Addex ADX71441 Demonstrates Statistically Significant Efficacy in a Highly Translational Preclinical Model of Chronic Osteoarthritis Pa.

09.01.17 07:05
Addex ADX71441 Demonstrates Statistically Significant Efficacy in a Highly Translational Preclinical Model of Chronic Osteoarthritis Pain

Addex Therapeutics /Addex ADX71441 Demonstrates Statistically Significant Efficacy in a Highly Translational Preclinical Model of Chronic Osteoarthritis Pain . Processed and transmitted by Nasdaq Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Geneva, Switzerland, 9 January 2017 - Addex Therapeutics (SIX: ADXN), announced today that ADX71441, a positive allosteric modulator (PAM) of the gamma-aminobutyric acid subtype B (GABAB) receptor demonstrated statistically significant efficacy in a highly translational preclinical model of chronic osteoarthritis pain.

ADX71441 and celecoxib, a COX-2 selective nonsteroidal anti-inflammatory drug were studied in the monosodium iodoacetate (MIA) model of chronic osteoarthritis pain for their anti-hyperalgesic effects. ADX71441 at doses of 0.3, 1, 3, and 15 mg/kg orally administered showed statistically significant efficacy 21 days post MIA administration. At 15 mg/kg the effect is similar to that observed with 30 mg/kg of celecoxib (P<0.01).

The study also demonstrated that ADX71943, a more peripherally restricted GABAB PAM compound, was more effective at early stages, presumably when the osteoarthritis pain is at a more inflammatory phase. While ADX71441, the more centrally active compound, was more effective at later stages, presumably when the osteoarthritis pain is at a more chronic neuropathic phase. Details of these data were published in European Journal of Pharmacology (Kalinichev et al, December 2016; available online).

"The efficacy demonstrated by ADX71441 in this chronic pain model, comparable to that obtained with the gold standard celecoxib, strongly supports the use of ADX71441 to treat chronic neuropathic pain," said Robert Lütjens, Head of Discovery at Addex. "ADX71441 has completed preclinical development and is scheduled to start Phase 1 this year."

"This recent publication in the European Journal of Pharmacology is a further demonstration of the quality of the science at Addex," said Tim Dyer, CEO of Addex. "While we focus on advancing ADX71441 in Phase 1 for addiction, we continue to profile other GABAB PAM compounds in multiple indications, including CMT1A neuropathy and pain."

GABAB receptor is clinically & commercially validated. Generic GABAB receptor agonist, baclofen, is marketed for spasticity and some spinal cord injuries, and French health authorities have approved its use for the treatment of alcoholism. Baclofen is also used off label for a number of other indications including overactive bladder (OAB), but its utility is limited due to variety of side effects and rapid clearance, requiring frequent administration of higher doses.

ADX71441 is a potent selective positive allosteric modulator (PAM) which potentiates GABA responses at the GABAB receptor. ADX71441 is a novel, first-in-class, oral, small molecule that demonstrated excellent preclinical efficacy and tolerability in rodent models of pain, anxiety, OAB, alcohol use disorders, nicotine dependence and in a non-human primate model of cocaine use disorder. ADX71441 has also proven efficacy in a genetic model of Charcot-Marie-Tooth Type 1A disease (CMT1A). ADX71441 has a different molecular mechanism from the generic drug baclofen in that it is a positive allosteric modulator, rather than an orthosteric agonist at the GABAB receptor, with a longer half-life, suitable for once daily administration. ADX71441 only acts when the natural ligand (GABA) activates the receptor, therefore respecting the physiological cycle of activation. It has been proposed that PAMs produce less adverse effects and lead to less tolerance than direct agonists.

Addex Therapeutics ( is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention - the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform. Addex's lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a phase 2A POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID with support from the Michael J. Fox Foundation for Parkinson's Research (MJFF). In parallel, dipraglurant's therapeutic use in dystonia is being investigated with support from the Dystonia Medical Research Foundation (DMRF). Addex's second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for epilepsy. In addition, ADX71441 (GABAB receptor PAM) has received regulatory approval to start Phase 1 and is being investigated for its therapeutic use in Charcot-Marie-Tooth Type 1A disease (CMT1A), cocaine and alcohol use disorder and nicotine dependence. Discovery programs include mGluR4PAM for neurodegenerative diseases, mGluR7NAM for psychosomatic disorders and TrkBPAM for neurodegenerative disorders which are being advanced in collaboration with the Universities of Lausanne and Geneva under the Swiss CTI grant program; and mGluR3PAM which is being advanced in collaboration with Pierre Fabre Pharmaceuticals.


Tim Dyer

Chief Executive Officer

Addex Therapeutics

Telephone: +41 22 884 15 61


Disclaimer / Forward-looking statements: This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Addex Therapeutics Ltd. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Addex Therapeutics via Globenewswire

--- End of Message ---

Addex Therapeutics

12, chemin des Aulx Plan-les-Ouates; Geneva Switzerland

ISIN: CH0029850754;


Breaking News

Kurs- und weitere Informationen zum Thema:

Addex Pharma

Aktuelle Diskussionen zum Thema:

Addex Therapeutics: Wann fliegt ... (20.03.18)
Addex, Valor 2985075 (15.08.16)

Aktuelle Nachrichten zum Unternehmen:

Alle Nachrichten zum Unternehmen

Aktuelle Analysen zu den Unternehmen:

Addex Pharma
Weitere Meldungen
10.01 L'ORÉAL: News Release: "L.
10.01 EQS-Adhoc: ACRON HELVE.
09.01 EVS Broadcast Equipment: .
09.01 Agfa-Gevaert : Classic Fund.
09.01 EQS-Adhoc: LifeWatch AG:.
09.01 Ad hoc: MAX 21 AG führt.
09.01 Ad hoc: Accentro Real Esta.
09.01 Ad hoc: PANTALEON Ente.
09.01 Ad hoc: Bijou Brigitte modis.
09.01 Ad hoc: PNE WIND AG ve.
09.01 Ad hoc: Neschen AG: Verä.
09.01 Outotec and Outokumpu sett.
09.01 The European Patent Office.
09.01 Ahold Delhaize commences .
09.01 Cancellation of Extraordinary.
09.01 TGS Q4 2016 Update and .
09.01 SOITEC : Launch of the rev.
09.01 DBV Technologies Announce.
09.01 Addex ADX71441 Demonstr.
09.01 Takeda notifies 4.48% share.
09.01 DNO Makes Cretaceous Oil .
08.01 Ad hoc: Die Geschäftsführu.
07.01 Ad hoc: Fresenius Medical C.
06.01 Ad hoc: Pütz Vermögensver.
06.01 Ad hoc: Pelikan Aktiengesel.
06.01 Ad hoc: AG: .
06.01 Akastor ASA: Akastor com.
06.01 Ad hoc: Medios AG: Vollstä.

Welche Social Networks nutzen Sie meistens?
Linked in

Stimmen: 43486 , Ergebnis

Status: nicht eingeloggt

Registrieren | Passwort vergessen?
Im Bereich Nachrichten:
Platin: Jahresendrallye gestartet?
Experte: Stefan Hofmann, STOCK-WORLD
Gold - Jede Wunderpille ...
Philip Hopf, Hopf Klinkmüller Capital. (15.12.18)
Experte: Philip Hopf, Hopf Klinkmüller Capital Management K.
Leoni: Voll-Voll-Volltreffer! ...
RuMaS, (15.12.18)
Experte: RuMaS,
Wie haben wir das nur ...
Bernd Niquet, Autor (15.12.18)
Experte: Bernd Niquet, Autor
Kaufsignal Gold: Kursziel ...
Claus Vogt, (15.12.18)
Experte: Claus Vogt,
Entspannung im ...
Börse Stuttgart AG, (15.12.18)
Experte: Börse Stuttgart AG,
Profitiert der Bund-Future ...
Sven Weisenhaus, Stockstreet GmbH (15.12.18)
Experte: Sven Weisenhaus, Stockstreet GmbH
Rohstoffe: Anleger ...
Redaktion boerse-frankf., Deutsche Börse AG (15.12.18)
Experte: Redaktion, Deutsche Börse AG
Lenovo: Ein Wunder?
Robert Sasse, (15.12.18)
Experte: Robert Sasse,
Wirecard-Aktie: Das ...
Volker Gelfarth, (15.12.18)
Experte: Volker Gelfarth,
Tritt Italien aus dem Euro ...
Frank Schäffler, (15.12.18)
Experte: Frank Schäffler,
DOW DAX abgeprallt
Thomas Heydrich, (14.12.18)
Experte: Thomas Heydrich,
Shortsignal beim Euro – ...
Till Kleinlein, (14.12.18)
Experte: Till Kleinlein,
Niquet's World
Neues vom Portal
Die Geldanlage: Eine kleine Einführung
Letzte Börsen-Meldung
Letzte Börsen-Analyse
Top-Klicks News
Top-Klicks Analysen